ArticleEuropean urology2016
Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Article in European urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02799303 (A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening), which is not on this map. Cited by 76 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening: The MVP Study (MRI vs PSA)
Who cites it
76 citing papers in PubMed, 3 syntheses or guidelines pooled it, 186 citations in OpenAlex.
- Refining biopsy strategies stratified by PI-RADS score in men: a systematic review and network meta-analysis.Nature communications · 2026Pooled it
- Exploring the potential clinical value of shear wave elastography in prostate cancer: a meta-analysis.BMC cancer · 2025Pooled it
- [MRI/TRUS fusion-guided prostate biopsy : Value in the context of focal therapy].Der Urologe. Ausg. A · 2017Pooled it
- [PREFERE - Study on the rise].Der Urologe. Ausg. A · 2016Trial
- Infection risks and biopsy-associated complications in prostate cancer diagnosis: a review of recent literatures.Prostate cancer and prostatic diseases · 2026Review
- Novel ultrasound scoring system to guide cognitive fusion-targeted biopsy: a prospective study.Abdominal radiology (New York) · 2025Article
- Enhanced detection of clinically significant prostate cancer in targeted and non-targeted regions using BiopSeeAmerican journal of clinical and experimental urology · 2025Article
- In Vivo Feasibility Study: Evaluating Autonomous Data-Driven Robotic Needle Trajectory Correction in MRI-Guided Transperineal Procedures.IEEE robotics and automation letters · 2024Article
- Development and validation of a predictive model based on clinical and MpMRI findings to reduce additional systematic prostate biopsy.Insights into imaging · 2024Article
- Lesion volume on multiparametric magnetic resonance imaging as a non-invasive prognosticator for clinically significant prostate cancer.Central European journal of urology · 2024Article
- Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy.Exploration of targeted anti-tumor therapy · 2024Review
- [Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023Article
- Learning curve for magnetic resonance imaging/ultrasound fusion prostate biopsy in detecting prostate cancer using cumulative sum analysis.Current urology · 2023Article
- Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.International urology and nephrology · 2023Article
- Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis.World journal of urology · 2023Article
- Temporal changes of PIRADS scoring by radiologists and correlation to radical prostatectomy pathological outcomes.Prostate international · 2022Article
- Axumin (World journal of urology · 2022Article
- Article
- Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Antitumor Proliferation and Related Mechanism of Ultrasound Irradiation Combined with Safflower Yellow.Computational intelligence and neuroscience · 2022Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIncreasing evidence supports the use of magnetic resonance imaging (MRI)-ultrasound fusion-targeted prostate biopsy (MRF-TB) to improve the detection of clinically significant prostate cancer (PCa) while limiting detection of indolent disease compared to systematic 12-core biopsy (SB).
objectiveTo compare MRF-TB and SB results and investigate the relationship between biopsy outcomes and prebiopsy MRI. DESIGN, SETTING, AND
participantsRetrospective analysis of a prospectively acquired cohort of men presenting for prostate biopsy over a 26-mo period. A total of 601 of 803 consecutively eligible men were included.
interventionsAll men were offered prebiopsy MRI and assigned a maximum MRI suspicion score (mSS). Men with an MRI abnormality underwent combined MRF-TB and SB. OUTCOMES: Detection rates for all PCa and high-grade PCa (Gleason score [GS] ≥7) were compared using the McNemar test. RESULTS AND LIMITATIONS: MRF-TB detected fewer GS 6 PCas (75 vs 121; p<0.001) and more GS ≥7 PCas (158 vs 117; p<0.001) than SB. Higher mSS was associated with higher detection of GS ≥7 PCa (p<0.001) but was not correlated with detection of GS 6 PCa. Prediction of GS ≥7 disease by mSS varied according to biopsy history. Compared to SB, MRF-TB identified more GS ≥7 PCas in men with no prior biopsy (88 vs 72; p=0.012), in men with a prior negative biopsy (28 vs 16; p=0.010), and in men with a prior cancer diagnosis (42 vs 29; p=0.043). MRF-TB detected fewer GS 6 PCas in men with no prior biopsy (32 vs 60; p<0.001) and men with prior cancer (30 vs 46; p=0.034). Limitations include the retrospective design and the potential for selection bias given a referral population.
conclusionsMRF-TB detects more high-grade PCas than SB while limiting detection of GS 6 PCa in men presenting for prostate biopsy. These findings suggest that prebiopsy multiparametric MRI and MRF-TB should be considered for all men undergoing prostate biopsy. In addition, mSS in conjunction with biopsy indications may ultimately help in identifying men at low risk of high-grade cancer for whom prostate biopsy may not be warranted. PATIENT SUMMARY: We examined how magnetic resonance imaging (MRI)-targeted prostate biopsy compares to traditional systematic biopsy in detecting prostate cancer among men with suspicion of prostate cancer. We found that MRI-targeted biopsy detected more high-grade cancers than systematic biopsy, and that MRI performed before biopsy can predict the risk of high-grade cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.